MedTrace Logo

Repurposing a Histamine Antagonist to Benefit Patients With Pulmonary Hypertension

NCT03554291 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-08-09

Study results available
· View outcomes & findings →

Summary

This is a Phase 2, single-center, randomized placebo controlled trial of famotidine (an H2 receptor antagonist) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of famotidine.

Conditions

Interventions

DRUG

Famotidine 20 MG

Famotidine 20 mg capsule taken daily for 24 weeks.

OTHER

Placebo

Placebo capsule taken daily for 24 weeks.

Sponsors & Collaborators

Principal Investigators

  • Peter J Leary, MD, PhD · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2023-07-11
Completion
2023-07-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03554291 on ClinicalTrials.gov